{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n", " from tqdm.autonotebook import tqdm, trange\n" ] } ], "source": [ "from sentence_transformers import SentenceTransformer, util\n", "import pandas as pd\n", "import re" ] }, { "cell_type": "code", "execution_count": 2, "metadata": {}, "outputs": [], "source": [ "# Target列を分割する関数\n", "def split_target(target):\n", " # 指定された区切り文字で分割\n", " split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n", " # 空白文字を除外してリストとして返す\n", " return [word.strip() for word in split_words if word.strip()]" ] }, { "cell_type": "code", "execution_count": 3, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n", "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n", "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['Target'].apply(split_target)" ] }, { "cell_type": "code", "execution_count": 4, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n", " warnings.warn(\n" ] } ], "source": [ "# モデルのロード\n", "model = SentenceTransformer('all-MiniLM-L6-v2')" ] }, { "cell_type": "code", "execution_count": 9, "metadata": {}, "outputs": [], "source": [ "# クエリ\n", "#query = \"乳がん\"\n", "query = \"神経膠腫\"\n", "threshold = 0.7\n", "# クエリをベクトル化\n", "query_vec = model.encode(query, convert_to_tensor=True)\n" ] }, { "cell_type": "code", "execution_count": 10, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
72jRCT2051240141NCT05580562NaN新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...H3 K27M 変異を有する初発びまん性神経膠腫H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...3NaN無作為化比較二重盲検...treatment purpose1. Able to understand the study procedures and...1. Primary spinal tumor.\\r\\n2. Diffuse intrins...No limitNo limitNaNNaNNaNParticipants will be randomized at baseline in...[H3 K27M 変異を有する初発, ん性神経膠腫]
103jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...悪性神経膠腫放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN無作為化比較非盲検...treatment purposeSubjects required to meet all the folloiwng cr...Patients who meets any of the following criter...No limit21age old notNaNNaNNaNDrug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...[悪性神経膠腫]
224jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...3NaN無作為化比較非盲検...treatment purpose1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy\\r\\nDepending on the patie...[悪性神経膠腫]
286jRCT2071230124NCT06541665NaNONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...中枢神経系原発リンパ腫未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...1NaN単一群非盲検...treatment purpose1. Patients diagnosed with PCNSL\\r\\n2. Patient...1.Patients with intraocular PCNSL without brai...18age old overNo limitBothNaNNaNConcomitant administration of ONO-4059 and rit...[中枢神経系原発リンパ腫]
321jRCT2071230114NCT06240741NaN日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...神経内分泌腫瘍（NEN）神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...3NaN単一群非盲検...diagnostic purpose1. Signed informed consent must be obtained pr...1. Inability to complete the needed investigat...18age old overNo limitBothNaNNaN[68Ga]Ga-DOTA-TATE will be administered intrav...[神経内分泌腫瘍（NEN）]
370jRCT2031230511NaNNaNDAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を...肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\...パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡...1NaN非無作為化比較非盲検...treatment purpose- Male or female participants >=18 years old a...- Previous treatment in this trial\\r\\n- Curren...18age old overNo limitBothNaNNaNConfidential information[肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く...
387jRCT2031230456NaNNaNJCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし...消化器（消化管・肝胆膵）神経内分泌癌切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ...3NaN無作為化比較非盲検...treatment purpose1) Histologically confirmed neuroendocrine car...1) Synchronous or metachronous malignancies\\r\\...18age old over75age old underNaNNaNNaNArm A: Six courses of etoposide + carboplatin ...[消化器（消化管, 肝胆膵）神経内分泌癌]
459jRCT2031230277NaNNaNメトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ...中枢神経系原発悪性リンパ腫寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた...2NaN無作為化比較二重盲検...treatment purpose1) Histopathological diagnosis of B cell lymph...1) Synchronous or metachronous malignancies.\\r...18age old overNo limitNaNNaNNaNTirabrutinib (480 mg) or placebo taken orally ...[中枢神経系原発悪性リンパ腫]
473jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...1NaN単一群非盲検...treatment purpose<Cohort 1>\\r\\n All of the following items shal...<Common to Cohort 1 and Cohort 2>\\r\\n1) Active...18age old overNo limitBothNaNNaN<cohort1>\\r\\nLomustine 130 mg/m2 orally every ...[神経膠腫]
529jRCT2032230060NaNNaN初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...2NaN単一群非盲検...treatment purposeAt the time of enrollment, patients will be in...Any of the following conditions shall not appl...18age old overNo limitBothNaNGliomaThe patient using the product should shave all...[IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）]
549jRCT2031230007NaNNaNBRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...低悪性度神経膠腫、膵癌BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...2NaN単一群非盲検...treatment purposeInclusion criteria for both cohort A and B\\r\\n...1) Active double primary cancer (but not (1)-(...12age old overNo limitBothNaNBRAF fusion gene, BRAF rearrangement, low-grad...Binimetinib is administered 45 mg orally, twic...[低悪性度神経膠腫, 膵癌]
563jRCT2031220716NaNNaNDLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍の患者を対象としたBI 764532と...DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍用量-毒性関係を評価し，ezabenlimab併用下でのBI 764532の最大耐量（MTD...1NaN非無作為化比較非盲検...treatment purposea)Signed and dated, written informed consent f...a)Previous treatment with T cell engagers or c...18age old overNo limitBothNaNNaNConfidential information[DLL3を発現する小細胞肺癌, その他の神経内分泌腫瘍]
633jRCT2031220511NCT05619744NaN進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬...小細胞肺癌及びその他の神経内分泌癌非盲検多施設共同第Ⅰ相臨床試験1NaN単一群非盲検...treatment purpose-Life expectancy at least 12 weeks\\r\\n-Eastern...-History or clinical evidence of primary centr...18age old overNo limitBothNaNNaNRO7616789: RO7616789 is administered as a intr...[小細胞肺癌, その他の神経内分泌癌]
875jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN単一群非盲検...treatment purpose1.\\tEstimated life expectancy >= 3 months\\r\\n2...1.\\tPrior therapy with bevacizumab or other an...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...[再発悪性神経膠腫]
\n", "

14 rows × 39 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "72 jRCT2051240141 NCT05580562 NaN \n", "103 jRCT2051240121 NCT06413706 NaN \n", "224 jRCT2031240090 NaN NaN \n", "286 jRCT2071230124 NCT06541665 NaN \n", "321 jRCT2071230114 NCT06240741 NaN \n", "370 jRCT2031230511 NaN NaN \n", "387 jRCT2031230456 NaN NaN \n", "459 jRCT2031230277 NaN NaN \n", "473 jRCT2051230069 NaN NaN \n", "529 jRCT2032230060 NaN NaN \n", "549 jRCT2031230007 NaN NaN \n", "563 jRCT2031220716 NaN NaN \n", "633 jRCT2031220511 NCT05619744 NaN \n", "875 jRCT2031210299 NaN NaN \n", "\n", " Title \\\n", "72 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n", "103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n", "224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n", "286 ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40... \n", "321 日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを... \n", "370 DAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を... \n", "387 JCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし... \n", "459 メトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ... \n", "473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", "529 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n", "549 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n", "563 DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍の患者を対象としたBI 764532と... \n", "633 進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬... \n", "875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n", "\n", " Target \\\n", "72 H3 K27M 変異を有する初発びまん性神経膠腫 \n", "103 悪性神経膠腫 \n", "224 悪性神経膠腫 \n", "286 中枢神経系原発リンパ腫 \n", "321 神経内分泌腫瘍（NEN） \n", "370 肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\... \n", "387 消化器（消化管・肝胆膵）神経内分泌癌 \n", "459 中枢神経系原発悪性リンパ腫 \n", "473 神経膠腫 \n", "529 IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫） \n", "549 低悪性度神経膠腫、膵癌 \n", "563 DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍 \n", "633 小細胞肺癌及びその他の神経内分泌癌 \n", "875 再発悪性神経膠腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n", "72 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... 3 NaN \n", "103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN \n", "224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 3 NaN \n", "286 未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及... 1 NaN \n", "321 神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT... 3 NaN \n", "370 パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡... 1 NaN \n", "387 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ... 3 NaN \n", "459 寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた... 2 NaN \n", "473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN \n", "529 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... 2 NaN \n", "549 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... 2 NaN \n", "563 用量-毒性関係を評価し，ezabenlimab併用下でのBI 764532の最大耐量（MTD... 1 NaN \n", "633 非盲検多施設共同第Ⅰ相臨床試験 1 NaN \n", "875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN \n", "\n", " 無作為化 盲検化 ... purpose \\\n", "72 無作為化比較 二重盲検 ... treatment purpose \n", "103 無作為化比較 非盲検 ... treatment purpose \n", "224 無作為化比較 非盲検 ... treatment purpose \n", "286 単一群 非盲検 ... treatment purpose \n", "321 単一群 非盲検 ... diagnostic purpose \n", "370 非無作為化比較 非盲検 ... treatment purpose \n", "387 無作為化比較 非盲検 ... treatment purpose \n", "459 無作為化比較 二重盲検 ... treatment purpose \n", "473 単一群 非盲検 ... treatment purpose \n", "529 単一群 非盲検 ... treatment purpose \n", "549 単一群 非盲検 ... treatment purpose \n", "563 非無作為化比較 非盲検 ... treatment purpose \n", "633 単一群 非盲検 ... treatment purpose \n", "875 単一群 非盲検 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "72 1. Able to understand the study procedures and... \n", "103 Subjects required to meet all the folloiwng cr... \n", "224 1) Histologically diagnosed as high grade glio... \n", "286 1. Patients diagnosed with PCNSL\\r\\n2. Patient... \n", "321 1. Signed informed consent must be obtained pr... \n", "370 - Male or female participants >=18 years old a... \n", "387 1) Histologically confirmed neuroendocrine car... \n", "459 1) Histopathological diagnosis of B cell lymph... \n", "473 \\r\\n All of the following items shal... \n", "529 At the time of enrollment, patients will be in... \n", "549 Inclusion criteria for both cohort A and B\\r\\n... \n", "563 a)Signed and dated, written informed consent f... \n", "633 -Life expectancy at least 12 weeks\\r\\n-Eastern... \n", "875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "72 1. Primary spinal tumor.\\r\\n2. Diffuse intrins... No limit \n", "103 Patients who meets any of the following criter... No limit \n", "224 1) Have a history or merger of other malignanc... 18age old over \n", "286 1.Patients with intraocular PCNSL without brai... 18age old over \n", "321 1. Inability to complete the needed investigat... 18age old over \n", "370 - Previous treatment in this trial\\r\\n- Curren... 18age old over \n", "387 1) Synchronous or metachronous malignancies\\r\\... 18age old over \n", "459 1) Synchronous or metachronous malignancies.\\r... 18age old over \n", "473 \\r\\n1) Active... 18age old over \n", "529 Any of the following conditions shall not appl... 18age old over \n", "549 1) Active double primary cancer (but not (1)-(... 12age old over \n", "563 a)Previous treatment with T cell engagers or c... 18age old over \n", "633 -History or clinical evidence of primary centr... 18age old over \n", "875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "72 No limit NaN NaN \n", "103 21age old not NaN NaN \n", "224 75age old under Both NaN \n", "286 No limit Both NaN \n", "321 No limit Both NaN \n", "370 No limit Both NaN \n", "387 75age old under NaN NaN \n", "459 No limit NaN NaN \n", "473 No limit Both NaN \n", "529 No limit Both NaN \n", "549 No limit Both NaN \n", "563 No limit Both NaN \n", "633 No limit Both NaN \n", "875 No limit Both NaN \n", "\n", " Keyword \\\n", "72 NaN \n", "103 NaN \n", "224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "286 NaN \n", "321 NaN \n", "370 NaN \n", "387 NaN \n", "459 NaN \n", "473 NaN \n", "529 Glioma \n", "549 BRAF fusion gene, BRAF rearrangement, low-grad... \n", "563 NaN \n", "633 NaN \n", "875 NaN \n", "\n", " Intervention(s) \\\n", "72 Participants will be randomized at baseline in... \n", "103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n", "224 Group A: BPC Therapy\\r\\nDepending on the patie... \n", "286 Concomitant administration of ONO-4059 and rit... \n", "321 [68Ga]Ga-DOTA-TATE will be administered intrav... \n", "370 Confidential information \n", "387 Arm A: Six courses of etoposide + carboplatin ... \n", "459 Tirabrutinib (480 mg) or placebo taken orally ... \n", "473 \\r\\nLomustine 130 mg/m2 orally every ... \n", "529 The patient using the product should shave all... \n", "549 Binimetinib is administered 45 mg orally, twic... \n", "563 Confidential information \n", "633 RO7616789: RO7616789 is administered as a intr... \n", "875 Patients will receive DSP-0390 orally once dai... \n", "\n", " TargetWord \n", "72 [H3 K27M 変異を有する初発, ん性神経膠腫] \n", "103 [悪性神経膠腫] \n", "224 [悪性神経膠腫] \n", "286 [中枢神経系原発リンパ腫] \n", "321 [神経内分泌腫瘍（NEN）] \n", "370 [肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く... \n", "387 [消化器（消化管, 肝胆膵）神経内分泌癌] \n", "459 [中枢神経系原発悪性リンパ腫] \n", "473 [神経膠腫] \n", "529 [IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）] \n", "549 [低悪性度神経膠腫, 膵癌] \n", "563 [DLL3を発現する小細胞肺癌, その他の神経内分泌腫瘍] \n", "633 [小細胞肺癌, その他の神経内分泌癌] \n", "875 [再発悪性神経膠腫] \n", "\n", "[14 rows x 39 columns]" ] }, "execution_count": 10, "metadata": {}, "output_type": "execute_result" } ], "source": [ "# ターゲットリスト全体を処理\n", "matched_indices = []\n", "target_vecs_list = []\n", "cosine_scores_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " # ターゲット内の各単語をベクトル化\n", " target_vecs = model.encode(target_words, convert_to_tensor=True)\n", " # コサイン類似度を計算\n", " cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n", " target_vecs_list.append(target_vecs)\n", " cosine_scores_list.append(cosine_scores)\n", " # 閾値を超えるか確認\n", " if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n", " matched_indices.append(idx)\n", "\n", "# 抽出\n", "matched_df = basedf.iloc[matched_indices]\n", "matched_df" ] }, { "cell_type": "code", "execution_count": 11, "metadata": {}, "outputs": [], "source": [ "# 全データのターゲット列をベクトル化\n", "target_list = basedf['Target'].tolist()\n", "target_vecs = model.encode(target_list, convert_to_tensor=True)\n", "# コサイン類似度を計算\n", "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()" ] }, { "cell_type": "code", "execution_count": 13, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTarget研究・治験の目的試験等のフェーズ試験の種類無作為化盲検化...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWord
103jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...悪性神経膠腫放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN無作為化比較非盲検...treatment purposeSubjects required to meet all the folloiwng cr...Patients who meets any of the following criter...No limit21age old notNaNNaNNaNDrug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...[悪性神経膠腫]
224jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...3NaN無作為化比較非盲検...treatment purpose1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy\\r\\nDepending on the patie...[悪性神経膠腫]
286jRCT2071230124NCT06541665NaNONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...中枢神経系原発リンパ腫未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...1NaN単一群非盲検...treatment purpose1. Patients diagnosed with PCNSL\\r\\n2. Patient...1.Patients with intraocular PCNSL without brai...18age old overNo limitBothNaNNaNConcomitant administration of ONO-4059 and rit...[中枢神経系原発リンパ腫]
321jRCT2071230114NCT06240741NaN日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...神経内分泌腫瘍（NEN）神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...3NaN単一群非盲検...diagnostic purpose1. Signed informed consent must be obtained pr...1. Inability to complete the needed investigat...18age old overNo limitBothNaNNaN[68Ga]Ga-DOTA-TATE will be administered intrav...[神経内分泌腫瘍（NEN）]
370jRCT2031230511NaNNaNDAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を...肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\...パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡...1NaN非無作為化比較非盲検...treatment purpose- Male or female participants >=18 years old a...- Previous treatment in this trial\\r\\n- Curren...18age old overNo limitBothNaNNaNConfidential information[肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く...
387jRCT2031230456NaNNaNJCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし...消化器（消化管・肝胆膵）神経内分泌癌切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ...3NaN無作為化比較非盲検...treatment purpose1) Histologically confirmed neuroendocrine car...1) Synchronous or metachronous malignancies\\r\\...18age old over75age old underNaNNaNNaNArm A: Six courses of etoposide + carboplatin ...[消化器（消化管, 肝胆膵）神経内分泌癌]
459jRCT2031230277NaNNaNメトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ...中枢神経系原発悪性リンパ腫寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた...2NaN無作為化比較二重盲検...treatment purpose1) Histopathological diagnosis of B cell lymph...1) Synchronous or metachronous malignancies.\\r...18age old overNo limitNaNNaNNaNTirabrutinib (480 mg) or placebo taken orally ...[中枢神経系原発悪性リンパ腫]
473jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...1NaN単一群非盲検...treatment purpose<Cohort 1>\\r\\n All of the following items shal...<Common to Cohort 1 and Cohort 2>\\r\\n1) Active...18age old overNo limitBothNaNNaN<cohort1>\\r\\nLomustine 130 mg/m2 orally every ...[神経膠腫]
529jRCT2032230060NaNNaN初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...2NaN単一群非盲検...treatment purposeAt the time of enrollment, patients will be in...Any of the following conditions shall not appl...18age old overNo limitBothNaNGliomaThe patient using the product should shave all...[IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）]
549jRCT2031230007NaNNaNBRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...低悪性度神経膠腫、膵癌BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...2NaN単一群非盲検...treatment purposeInclusion criteria for both cohort A and B\\r\\n...1) Active double primary cancer (but not (1)-(...12age old overNo limitBothNaNBRAF fusion gene, BRAF rearrangement, low-grad...Binimetinib is administered 45 mg orally, twic...[低悪性度神経膠腫, 膵癌]
633jRCT2031220511NCT05619744NaN進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬...小細胞肺癌及びその他の神経内分泌癌非盲検多施設共同第Ⅰ相臨床試験1NaN単一群非盲検...treatment purpose-Life expectancy at least 12 weeks\\r\\n-Eastern...-History or clinical evidence of primary centr...18age old overNo limitBothNaNNaNRO7616789: RO7616789 is administered as a intr...[小細胞肺癌, その他の神経内分泌癌]
875jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN単一群非盲検...treatment purpose1.\\tEstimated life expectancy >= 3 months\\r\\n2...1.\\tPrior therapy with bevacizumab or other an...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...[再発悪性神経膠腫]
\n", "

12 rows × 39 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "103 jRCT2051240121 NCT06413706 NaN \n", "224 jRCT2031240090 NaN NaN \n", "286 jRCT2071230124 NCT06541665 NaN \n", "321 jRCT2071230114 NCT06240741 NaN \n", "370 jRCT2031230511 NaN NaN \n", "387 jRCT2031230456 NaN NaN \n", "459 jRCT2031230277 NaN NaN \n", "473 jRCT2051230069 NaN NaN \n", "529 jRCT2032230060 NaN NaN \n", "549 jRCT2031230007 NaN NaN \n", "633 jRCT2031220511 NCT05619744 NaN \n", "875 jRCT2031210299 NaN NaN \n", "\n", " Title \\\n", "103 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n", "224 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n", "286 ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40... \n", "321 日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを... \n", "370 DAREON™-7：神経内分泌癌（NEC）患者の1次治療として，BI 764532点滴静注を... \n", "387 JCOG2107E: 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）を対象とし... \n", "459 メトトレキサート基盤寛解導入療法後奏効例の非照射初発中枢神経系原発悪性リンパ腫に対するチラブ... \n", "473 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", "529 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n", "549 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n", "633 進行小細胞肺癌及びその他の神経内分泌癌患者を対象としてRO7616789の安全性，忍容性，薬... \n", "875 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n", "\n", " Target \\\n", "103 悪性神経膠腫 \n", "224 悪性神経膠腫 \n", "286 中枢神経系原発リンパ腫 \n", "321 神経内分泌腫瘍（NEN） \n", "370 肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\... \n", "387 消化器（消化管・肝胆膵）神経内分泌癌 \n", "459 中枢神経系原発悪性リンパ腫 \n", "473 神経膠腫 \n", "529 IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫） \n", "549 低悪性度神経膠腫、膵癌 \n", "633 小細胞肺癌及びその他の神経内分泌癌 \n", "875 再発悪性神経膠腫 \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 \\\n", "103 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN \n", "224 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 3 NaN \n", "286 未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及... 1 NaN \n", "321 神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT... 3 NaN \n", "370 パートA：用量漸増の主要目的は，BI 764532の最大耐量（MTD）及び／又は目標用量の拡... 1 NaN \n", "387 切除不能・再発消化器（消化管・肝胆膵）神経内分泌癌（NEC）において、エトポシド＋カルボプラ... 3 NaN \n", "459 寛解導入療法として大量メトトレキサート（HD-MTX）基盤化学療法実施後に完全奏効（CRまた... 2 NaN \n", "473 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 1 NaN \n", "529 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... 2 NaN \n", "549 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... 2 NaN \n", "633 非盲検多施設共同第Ⅰ相臨床試験 1 NaN \n", "875 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN \n", "\n", " 無作為化 盲検化 ... purpose \\\n", "103 無作為化比較 非盲検 ... treatment purpose \n", "224 無作為化比較 非盲検 ... treatment purpose \n", "286 単一群 非盲検 ... treatment purpose \n", "321 単一群 非盲検 ... diagnostic purpose \n", "370 非無作為化比較 非盲検 ... treatment purpose \n", "387 無作為化比較 非盲検 ... treatment purpose \n", "459 無作為化比較 二重盲検 ... treatment purpose \n", "473 単一群 非盲検 ... treatment purpose \n", "529 単一群 非盲検 ... treatment purpose \n", "549 単一群 非盲検 ... treatment purpose \n", "633 単一群 非盲検 ... treatment purpose \n", "875 単一群 非盲検 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "103 Subjects required to meet all the folloiwng cr... \n", "224 1) Histologically diagnosed as high grade glio... \n", "286 1. Patients diagnosed with PCNSL\\r\\n2. Patient... \n", "321 1. Signed informed consent must be obtained pr... \n", "370 - Male or female participants >=18 years old a... \n", "387 1) Histologically confirmed neuroendocrine car... \n", "459 1) Histopathological diagnosis of B cell lymph... \n", "473 \\r\\n All of the following items shal... \n", "529 At the time of enrollment, patients will be in... \n", "549 Inclusion criteria for both cohort A and B\\r\\n... \n", "633 -Life expectancy at least 12 weeks\\r\\n-Eastern... \n", "875 1.\\tEstimated life expectancy >= 3 months\\r\\n2... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "103 Patients who meets any of the following criter... No limit \n", "224 1) Have a history or merger of other malignanc... 18age old over \n", "286 1.Patients with intraocular PCNSL without brai... 18age old over \n", "321 1. Inability to complete the needed investigat... 18age old over \n", "370 - Previous treatment in this trial\\r\\n- Curren... 18age old over \n", "387 1) Synchronous or metachronous malignancies\\r\\... 18age old over \n", "459 1) Synchronous or metachronous malignancies.\\r... 18age old over \n", "473 \\r\\n1) Active... 18age old over \n", "529 Any of the following conditions shall not appl... 18age old over \n", "549 1) Active double primary cancer (but not (1)-(... 12age old over \n", "633 -History or clinical evidence of primary centr... 18age old over \n", "875 1.\\tPrior therapy with bevacizumab or other an... 18age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "103 21age old not NaN NaN \n", "224 75age old under Both NaN \n", "286 No limit Both NaN \n", "321 No limit Both NaN \n", "370 No limit Both NaN \n", "387 75age old under NaN NaN \n", "459 No limit NaN NaN \n", "473 No limit Both NaN \n", "529 No limit Both NaN \n", "549 No limit Both NaN \n", "633 No limit Both NaN \n", "875 No limit Both NaN \n", "\n", " Keyword \\\n", "103 NaN \n", "224 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "286 NaN \n", "321 NaN \n", "370 NaN \n", "387 NaN \n", "459 NaN \n", "473 NaN \n", "529 Glioma \n", "549 BRAF fusion gene, BRAF rearrangement, low-grad... \n", "633 NaN \n", "875 NaN \n", "\n", " Intervention(s) \\\n", "103 Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt... \n", "224 Group A: BPC Therapy\\r\\nDepending on the patie... \n", "286 Concomitant administration of ONO-4059 and rit... \n", "321 [68Ga]Ga-DOTA-TATE will be administered intrav... \n", "370 Confidential information \n", "387 Arm A: Six courses of etoposide + carboplatin ... \n", "459 Tirabrutinib (480 mg) or placebo taken orally ... \n", "473 \\r\\nLomustine 130 mg/m2 orally every ... \n", "529 The patient using the product should shave all... \n", "549 Binimetinib is administered 45 mg orally, twic... \n", "633 RO7616789: RO7616789 is administered as a intr... \n", "875 Patients will receive DSP-0390 orally once dai... \n", "\n", " TargetWord \n", "103 [悪性神経膠腫] \n", "224 [悪性神経膠腫] \n", "286 [中枢神経系原発リンパ腫] \n", "321 [神経内分泌腫瘍（NEN）] \n", "370 [肺外神経内分泌癌（, だしメルケル細胞癌，甲状腺髄様癌, グレード3の神経内分泌腫瘍を除く... \n", "387 [消化器（消化管, 肝胆膵）神経内分泌癌] \n", "459 [中枢神経系原発悪性リンパ腫] \n", "473 [神経膠腫] \n", "529 [IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）] \n", "549 [低悪性度神経膠腫, 膵癌] \n", "633 [小細胞肺癌, その他の神経内分泌癌] \n", "875 [再発悪性神経膠腫] \n", "\n", "[12 rows x 39 columns]" ] }, "execution_count": 13, "metadata": {}, "output_type": "execute_result" } ], "source": [ "matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n", "# 入れ子リストをフラットなリストに変換\n", "flat_indices_d = [idx[0] for idx in matched_indices_d]\n", "\n", "# 抽出\n", "matched_df_d = basedf.iloc[flat_indices_d]\n", "matched_df_d\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }